Evaluation of some biomarkers levels in women suffering from irritable bowel syndrome
DOI:
https://doi.org/10.36320/ajb/v18.i1.23163Keywords:
Irritable bowel syndrome ; age ; disease durationAbstract
Abstract: This study was conducted to provide an approach for the diagnosis and prognosis of irritable bowel syndrome , with a particular focus on serotonin . The research was conducted in Najaf Governorate, Iraq, from July 1, 2025, to December 1, 2026 . A total of 90 participants were enrolled, including 60 patients diagnosed with IBS and 30 healthy individuals as controls. The results were stratified into subgroups according to age, body mass index , disease duration , diagnosis status (newly diagnosed or under treatment), familial or non , constipation or diarrhea , physical activity and non-physical activity. The results revealed a significant decrease in serotonin level among patients compared to the control group. The present results revealed significant decrease in serotonin in women patients in compare with control . In ages groups that results showed significant decrease in ages group (20-29) years than other groups , also significant decrease in diarrhea group in compare to constipation . The results also indicated a significant decrease in new diagnosed patients than treated ,also body mass index revealed a significant decrease in obese patients than overweight . Shorter duration of disease less than (1 year) showed significant decrease than long more than 1 year . both physical activity and familial status showed a significant decrease than non physical activity and non familial , In conclusion, the study suggests that serotonin is a novel biomarker for irritable bowel syndrome It may serve as a valuable diagnostic and prognostic tool.
Downloads
References
1. Almansour, O. (2024). Prevalence of Irritable Bowel Syndrome (IBS) in the Arab World: A Systematic Review. Cureus, 16(7).
2. Zhang, Y., Wang, N., Zhang, L., Zhuang, Y., Xin, Q., Gu, X., ... & Wu, J. (2025). Serotonin (5‐Hydroxytryptamine): Metabolism, Signaling, Biological Functions, Diseases, and Emerging Therapeutic Opportunities. MedComm, 6(9), e70383.
3. Kerckhoffs, A. P., ter Linde, J. J., Akkermans, L. M., & Samsom, M. (2012). SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. American Journal of Physiology-Gastrointestinal and Liver Physiology, 302(9), G1053-G1060.
4. Cîmpeanu, R. C., Boldeanu, M. V., Ahrițculesei, R. V., Ciobanu, A. E., Cristescu, A. M., Forțofoiu, D., ... & Vere, C. C. (2024). Correlation between neurotransmitters (dopamine, epinephrine, norepinephrine, serotonin), prognostic nutritional index, Glasgow prognostic score, systemic inflammatory response markers, and TNM staging in a cohort of colorectal neuroendocrine tumor patients. International Journal of Molecular Sciences, 25(13), 6977
5. Al-Ani, W. Y. M., & Ghanem, N. J. (2025). The effect of serotonin and cholecystokinin in men with irritable bowel syndrome. International Journal of Pharmaceutical Sciences Review and Research, 13(1), 7–10. Retrieved from www.globalresearchonline.net
6. Dothel, G., Barbaro, M. R., Raschi, E., Barbara, G., & De Ponti, F. (2018). Advancements in elucidating the pathophysiological link between gut and brain in visceral pain. Neurogastroenterology & Motility, 30(8), e13463.
7. Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020). Irritable bowel syndrome. The Lancet, 396(10263), 1675-1688.
8. Kamp, E. H., Kane, J. S., & Ford, A. C. (2021). Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology, 19(3), 553-560.
9. Naji, N. N., Alhusayni, M. T., & Al-Tamimi, A. K. (2022). Role of serotonin hormone, TIMP-1, and CXCL-1 in diagnosis and differentiation types of irritable bowel syndrome. International Journal of Medical Studies. https://doi.org/10.25259/IJMS292022
10. Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther 2022;56(5):844 56. https://doi.org/10.1111/apt.17132
11. Tang HY, Jiang AJ, Wang XY, Wang H, Guan YY, Li F, et al. Uncovering the pathophys iology of irritable bowel syndrome by exploring the gut brain axis: A narrative review. Ann Transl Med 2021;9(14):1187. https://doi.org/10.21037/atm 21 2779
12. Spohn SN, Mawe GM. Non conventional features of peripheral serotonin signal ling the gut and beyond. Nat Rev Gastroenterol Hepatol 2017;14(7):412 20. https://doi.org/10.1038/nrgastro.2017.51
13. Sharp T, Barnes NM. Central 5 HT receptors and their function; present and future. Neuropharmacology 2020;177:108155. https://doi.org/10.1016/j.neuropharm.2020.108155
14. Latorre E, Layunta E, Grasa L, Castro M, Pardo J, Gomollón F, et al. Intestinal sero tonin transporter inhibition by toll like receptor 2 activation. A feedback modulation. PLoS One 2016;11(12):e0169303. https://doi.org/10.1371/journal.pone.0169303
15. Thijssen AY, Mujagic Z, Jonkers DM, Ludidi S, Keszthelyi D, Hesselink MA, et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther 2016;43(2):272 82. https://doi.org/10.1111/apt.13459
16. Vahora IS, Tsouklidis N, Kumar R, Soni R, Khan S. How serotonin level fluctu ation affects the effectiveness of treatment in irritable bowel syndrome. Cureus 2020;12(8):e9871. https://doi.org/10.7759/cureus.9871
17. Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675–88. doi: 10.1016/ S0140-6736(20)31548-8
18. ChenM,RuanG,ChenL,YingS,LiG,XuF,etal.Neurotrans mitter and intestinal interactions: focus on the microbiota gut-brainaxisinirritablebowelsyndrome.FrontEndocrinol. 2022;13:817100. doi: 10.3389/fendo.2022.817100
19. Sarnoff RP, Hreinsson JP, Kim J, Sperber AD, Palsson OS, Bangdiwala SI, et al. Sex differences, menses-related symp toms and menopause in disorders of gut-brain interaction. Neurogastroenterol Motil. 2025;37(2):e14977. doi: 10.1111/ nmo.14977
20. GeL,LiuS,LiS,YangJ,HuG,XuC,etal.Psychologicalstress in inflammatory bowel disease: psychoneuroimmunological insights into bidirectional gut–brain communications. Front Immunol. 2022;13:1016578. doi: 10.3389/fimmu.2022.101 6578
21. Staudacher HM, Black CJ, Teasdale SB, Mikocka-Walus A, Keefer L. Irritable bowel syndrome and mental health comorbidity—approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol. 2023;20(9):582–96. doi: 10 .1038/s41575-023-00794-z
22. Zhang X, Jin WW, Wang HG. Correlation between the neu roendocrine axis, microbial species, inflammatory response, and gastrointestinal symptoms in irritable bowel syndrome. WorldJGastroenterol.2024;30(35):3985–95.doi:10.3748/ wjg.v30.i35.3985
23. Gros M, Gros B, Mesonero JE, Latorre E. Neurotransmit ter dysfunction in irritable bowel syndrome: emerging ap proaches for management. J Clin Med. 2021;10(15):3429. doi: 10.3390/jcm10153429
24. Smith RP, Easson C, Lyle SM, Kapoor R, Donnelly CP, Davidson EJ, et al. Gut microbiome diversity is associated with sleep physiology in humans. PLoS ONE. 2019;14(10):e0222394. doi: 10.1371/journal.pone.0222394
25. Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J. & TARGET Study Group. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. New England Journal of Medicine, 364(1), 22-32.
26. Qin, H. Y., Cheng, C. W., Tang, X. D., & Bian, Z. X. (2014). Impact of psychological stress on irritable bowel syndrome. World journal of gastroenterology: WJG, 20(39), 14126.
27. Grzesiak, M., Beszlej, J. A., Waszczuk, E., Szechtinski, M., Słowikowska-Hilczer, M., Frydecka, D., Dobosz, T., Jonkisz, A., Lebioda, A., Małodobra, M., & Minka, J. (2017). Serotonin-related gene variants in patients with irritable bowel syndrome and depressive or anxiety disorders. Gastroenterology Research and Practice, 2017, Article 9684760. https://doi.org/10.1155/2017/9684760
Downloads
Published
Issue
Section
License
Copyright (c) 2026 doaa_najim abood
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
